Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year
Open Access
- 10 June 1999
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (23) , 1781-1787
- https://doi.org/10.1056/nejm199906103402302
Abstract
In 1995, the two-part National Institute of Neurological Disorders and Stroke (NINDS) Recombinant Tissue Plasminogen Activator Stroke Study found that patients who were treated with tissue plasminogen activator (t-PA) within three hours after the onset of symptoms of acute ischemic stroke were at least 30 percent more likely than patients given placebo to have minimal or no disability three months after the stroke. It was unknown, however, whether the benefit would be sustained for longer periods.Keywords
This publication has 23 references indexed in Scilit:
- Intravenous Tissue Plasminogen Activator for Acute Ischemic StrokeStroke, 1998
- Generalized Efficacy of t-PA for Acute StrokeStroke, 1997
- A Systems Approach to Immediate Evaluation and Management of Hyperacute StrokeStroke, 1997
- Thrombolytic Therapy in Acute Ischemic StrokeNew England Journal of Medicine, 1997
- Use of a Global Test for Multiple Outcomes in Stroke Trials With Application to the National Institute of Neurological Disorders and Stroke t-PA Stroke TrialStroke, 1996
- Thrombolytic Therapy with Streptokinase in Acute Ischemic StrokeNew England Journal of Medicine, 1996
- Epidemiological characteristics of lacunar infarcts in a population.Stroke, 1991
- Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trialsPublished by American Medical Association (AMA) ,1991
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988
- Survival and recurrence following stroke. The Framingham study.Stroke, 1982